In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over ...

The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, ...

Leerink Partnrs has cut its Q3 2025 earnings estimate for Regeneron Pharmaceuticals, citing lowered expectations across the ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Ekterly comes in the form of a 300 mg tablet. The recommended dosage is 600 mg split into two doses taken at the earliest sign of an attack, according to the prescribing information. Additional ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.